- Home
- FEMY vs IOTR Comparison
FEMY vs IOTR Comparison
Compare FEMY & IOTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- IOTR
- Stock Information
- Founded
- FEMY 2004
- IOTR 2019
- Country
- FEMY United States
- IOTR Singapore
- Employees
- FEMY N/A
- IOTR N/A
- Industry
- FEMY Medical/Dental Instruments
- IOTR
- Sector
- FEMY Health Care
- IOTR
- Exchange
- FEMY Nasdaq
- IOTR NYSE
- Market Cap
- FEMY 29.9M
- IOTR 29.5M
- IPO Year
- FEMY 2021
- IOTR 2025
- Fundamental
- Price
- FEMY $0.92
- IOTR $0.52
- Analyst Decision
- FEMY Strong Buy
- IOTR
- Analyst Count
- FEMY 3
- IOTR 0
- Target Price
- FEMY $8.67
- IOTR N/A
- AVG Volume (30 Days)
- FEMY 257.9K
- IOTR 534.7K
- Earning Date
- FEMY 08-07-2025
- IOTR 01-01-0001
- Dividend Yield
- FEMY N/A
- IOTR N/A
- EPS Growth
- FEMY N/A
- IOTR N/A
- EPS
- FEMY N/A
- IOTR N/A
- Revenue
- FEMY $1,699,232.00
- IOTR $10,478,550.00
- Revenue This Year
- FEMY $283.83
- IOTR N/A
- Revenue Next Year
- FEMY $161.03
- IOTR N/A
- P/E Ratio
- FEMY N/A
- IOTR N/A
- Revenue Growth
- FEMY 61.97
- IOTR 22.27
- 52 Week Low
- FEMY $0.69
- IOTR $0.31
- 52 Week High
- FEMY $1.80
- IOTR $5.98
- Technical
- Relative Strength Index (RSI)
- FEMY 46.22
- IOTR N/A
- Support Level
- FEMY $0.91
- IOTR N/A
- Resistance Level
- FEMY $0.99
- IOTR N/A
- Average True Range (ATR)
- FEMY 0.05
- IOTR 0.00
- MACD
- FEMY 0.00
- IOTR 0.00
- Stochastic Oscillator
- FEMY 11.71
- IOTR 0.00
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.